MIMS summary of approval of dapagliflozin (Forxiga) to treat heart failure

Dapagliflozin is the first SGLT2 inhibitor to be licensed to treat symptomatic chronic heart failure in patients with reduced ejection fraction, based on evidence it significantly reduces risk of CV death and worsening of heart failure vs. placebo.

Monthly Index of Medical Specialities